Ketolides Global Market Report 2026

Ketolides are a group of antibiotics within the macrolide family that are derived from erythromycin, a 14-membered macrolide, by replacing the cladinose sugar with a keto group and adding a cyclic carbamate group to the lactone ring. They work by inhibiting protein synthesis, thereby preventing bacteria from producing essential proteins required for their growth and survival.

The main drugs classified as ketolides include telithromycin, cethromycin, and solithromycin. Telithromycin is a semi-synthetic antibiotic in the ketolide class that is used to treat respiratory tract infections. These medications are indicated for various conditions such as bronchitis, pneumonia, sinusitis, and tonsillitis or pharyngitis. They are effective against several types of microorganisms, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

Tariffs have influenced the ketolides market by increasing the cost of imported raw materials and active pharmaceutical ingredients (APIs), leading to higher production expenses and potential delays in drug availability. The hospital and retail pharmacy segments, particularly in regions like North America and Europe, are most affected due to their dependence on imported ketolides. Some manufacturers may benefit by localizing production and reducing reliance on international supply chains, promoting innovation and cost optimization in drug formulations.

The ketolides market research report is one of a series of new reports from The Business Research Company that provides ketolides market statistics, including ketolides industry global market size, regional shares, competitors with a ketolides market share, detailed ketolides market segments, market trends and opportunities, and any further data you may need to thrive in the ketolides industry. This ketolides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ketolides market size has grown steadily in recent years. It will grow from $3.32 billion in 2025 to $3.46 billion in 2026 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to increasing prevalence of bacterial infections, rise in respiratory tract infections, growing geriatric population, demand for alternatives to macrolide-resistant antibiotics, advancements in antibiotic research.

The ketolides market size is expected to see strong growth in the next few years. It will grow to $4.24 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to expansion of precision medicine applications, development of next-generation ketolides, increasing adoption in emerging markets, investment in antibiotic resistance research, growth in hospital and retail pharmacy networks. Major trends in the forecast period include development of novel ketolide derivatives, antibiotic resistance management, expansion of hospital and retail antibiotic usage, personalized antibiotic therapy, enhanced drug formulation and delivery systems.

The growing prevalence of infectious diseases is expected to drive the expansion of the ketolides market in the coming years. Infectious diseases are conditions caused by pathogens such as bacteria, viruses, fungi, or parasites that can be transmitted between individuals, resulting in a wide range of symptoms and health complications. Tuberculosis is one example of an infectious disease. Ketolides, which are used to treat infectious diseases, have been studied for their potential in treating tuberculosis due to their high levels of intracellular activity, which play a crucial role in combating the infection. For instance, in February 2024, data from GOV.UK, a UK-based government department, indicated that tuberculosis (TB) cases in England rose by 10.7% in 2023, increasing from 4,380 in 2022 to 4,850. Therefore, the increasing prevalence of infectious diseases is contributing to the growth of the ketolides market.

The growth of the healthcare industry is expected to further support the expansion of the ketolides market going forward. The healthcare industry encompasses the integrated sectors of the economy that provide products and services for treating, preventing, rehabilitating, and offering palliative care to patients. Expansion in this industry facilitates the development of ketolides by supporting research trials and providing guidance on the safety and efficacy of these drugs. Additionally, the healthcare sector plays a vital role in ensuring that patients receive ketolides safely and effectively. For instance, in May 2023, the American Health Care Association, a US-based nonprofit organization, reported that the number of hospitals in the United States increased to 6,129 in 2023 from 6,093 in 2022. Therefore, the growth of the healthcare industry is driving the expansion of the ketolides market.

Major companies operating in the ketolides market are concentrating on developing innovative drugs and treatments to maintain competitive advantages and strengthen their market position. For instance, in June 2023, AliquantumRx Inc., a US-based biotechnology research company, announced that the United States Patent and Trademark Office (USPTO), a US-based agency under the Department of Commerce, had approved its patent for "salts and polymorphs of cethromycin for the treatment of bacterial and protozoan diseases." Cethromycin, a ketolide antibiotic, is effective against a range of infectious diseases caused by bacteria and protozoa, including malaria, babesiosis, toxoplasmosis, and diarrhea. This new patent provides the company with additional opportunities to expand the use of cethromycin beyond malaria while reducing the commercialization risks associated with the drug.

Major companies operating in the ketolides market are Pfizer Inc., F. Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Shionogi & Company Limited, Dr. Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Corden Pharma GmbH, Optimer Pharmaceuticals Inc., Vivimed Labs Limited, Wockhardt Ltd., Advanced Life Sciences Holdings Inc

North America was the largest region in the ketolides market in 2025. The regions covered in the ketolides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ketolides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ketolides market consists of sales of solithera and ketek, arylalkyl and macrolactone rings. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ketolides Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ketolides market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ketolides ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ketolides market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Telithromycin; Cethromycin; Solithromycin
• 2) By Indication: Bronchitis; Pneumonia; Sinusitis; Tonsillitis Or Pharyngitis
• 3) By Microorganism: Streptococcus Pneumoniae; Haemophilus Influenzae; Moraxella Catarrhalis; Chlamydophila Pneumoniae; Mycoplasma Pneumoniae
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Companies Mentioned: Pfizer Inc.; F. Merck & Co. Inc.; Novartis AG; Sanofi S.A.; AstraZeneca PLC; Abbott Laboratories; GSK PLC; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Shionogi & Company Limited; Dr. Reddys Laboratories Ltd.; Glenmark Pharmaceuticals Ltd.; Corden Pharma GmbH; Optimer Pharmaceuticals Inc.; Vivimed Labs Limited; Wockhardt Ltd.; Advanced Life Sciences Holdings Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.